Key clinical point: Inotuzumab ozogamicin plus bosutinib may be effective against relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic and chronic myeloid leukemias in blast phase.
Major finding: The median overall survival was 15.4 months.
Study details: Phase 1/2 trial in 18 patients with Ph+ ALL or CML.
Disclosures: Dr. Jain has disclosed consultancy, honoraria, advisory board/committee activity, and research funding from Pfizer, maker of inotuzumab ozogamicin and bosutinib.
Jain N et al. EHA Congress, Abstract EP396.